Corcept Rehabs’ worth rapidly cut in half after the FDA denied medicine prospect relacorilant.
发布者：BY ULRICH QUISTGAARD，转转请注明出处：https://robotalks.cn/fda-rejects-drug-for-hormone-disorder/
关于作者
Evaxion CEO calls MSD rejection “disappointing, unfortunate, and surprising”
上一篇
3 1 月, 2026 11:19 下午
Outlook Therapeutics plunges after rejection from the FDA
下一篇
3 1 月, 2026 11:19 下午
相关推荐
-
OMODA y JAECOO superan las 43 mil ventas globales en noviembre; los NEV ya representan más de la mitad del volumen
/PRNewswire/ — OMODA y JAECOO cerraron noviembre con 43,481 unidades vendidas a nivel global, marcando un nuevo récord mensual y elevando el complete acumulado de enero a noviembre por encima de las 330 mil unidades, un crecimiento del 47% anual. Este avance confirma el posicionamiento sólido de ambas marcas en un entorno internacional cada
-
Cyberattack roundup: Ransomware hits Georgia hospital and Colorado pathology services
Additionally: Kaiser Permanente reported that an unauthorized get together gained entry to the e-mail accounts of two workforce members and seen affected person well being info.
-
Bluedrop Training & Simulation: Mastering Europe’s toughest missions
Off the shore of Norway, a rescue helicopter floats over an angling vessel captured in hefty seas. In the cabin, the hoist driver steadies the cord versus wind and spray, collabora…
-
Huawei collaborates with BBI in Building an Intelligent All-Optical Backbone Network to Advance South Africa’s National Broadband Strategy
South Africa’s national broadband infrastructure company Broadband Infraco (BBI) has partnered with Huawei to build a national intelligent all-optical backbone network. The n…
-
Revelstoke Capital Partners Announces Significant Growth Investment in MediQuant
Revelstoke Capital Partners, a healthcare-focused personal equity company, today revealed a substantial development financial investment in MediQuant, LLC, a leader in cloud-based …
